Achieving Commercial Success through the Implementation of Amorphous Techniques Amorphous pharmaceutical materials are now being recognised as an attractive alternative route for solid state development, partly due to the increasing proportion of insoluble drug molecules in development.
Owing to the lack of an ordered crystal lattice, amorphous forms require minimal energy and therefore offer
enhanced solubility, dissolution rate, and bioavailability properties which are all integral to the effectiveness and success of future medicines.
Currently, several amorphous drugs have made it to market, but in many cases stabilising amorphous systems while maintaining these physico-chemical advantages still remains a major challenge in the pharmaceutical arena.
For that reason,
Amorphous Pharmaceutical Materials 2010 will explore the results and knowledge acquired over the years on
perfecting the art of amorphous formation and stabilisation. This will thus ensure
consistency of amorphous drugs from the laboratory to manufacture, with the ultimate aim of
realising the commercial potential of amorphous forms in pharmaceutical drugs.The Expert Speaker Panel includes:
- Dr Marcus Brewster, Distinguished Research Fellow and Head of ChemPharm Research, Johnson & Johnson Pharmaceutical Research and Development
- Dr Brian Padden, Section Manager, Abbott Laboratories
- Dr Conrad Winters, Senior Director Pharmaceutics, Xenon Pharmaceuticals
- Dr Zeren Wang, Director Pharmaceutics, Boehringher Ingelheim
- Dr Anne Kavanagh, Crystallisation Scientist, AstraZeneca
- Mr Andrew Theophilus MRSC, Team Leader, Physical Properties and Analytical Sciences, GlaxoSmithKline
- Dr Brian Luisi, Research Scientist, Vertex Pharmaceuticals
- Dr Marco Gil, R & D Particle Design Senior Engineer, Hovione
Register by 18th June and receive up to 500 off!
